Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131

Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that it has enrolled the first patient in the diffuse large B-cell lymphoma cohort of its Phase 2 clinical trial of CLR 131, its lead radiotherapeutic Phospholipid Drug Conjugate.
As quoted in the press release:

“DLBCL is a rare hematologic cancer with few treatment options and the expansion of the Phase 2 trial provides the opportunity to further explore the broad treatment potential of CLR 131 in an area of significant unmet need. We are now exploring CLR 131 in six hematologic malignancies and we expect to initiate Phase 1 studies in head & neck cancer and pediatric tumors in 2018,” stated James Caruso, president and chief executive officer of Cellectar Biosciences.

Click here to read the full press release.